A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer

Objective: Calcium electroporation (CaEP) is a new technique whereby intracellular concentrations of calcium are elevated by transient permeabilisation of the cell membrane using high-voltage electrical pulses. Tumour necrosis is induced with little damage to healthy tissue. Within gynaecological cancer, vulval cancer and vulval intraepithelial neoplasia (VIN) pose challenges for treatment, given the high recurrence rate, persistent symptoms and repeated resections required. In certain cases, CaEP may provide a suitable alternative. Methods: We present a case series of six patients with recurrent vulval squamous cell carcinoma (n = 2), VIN III (n = 2) and metastatic ovarian cancer (n = 2), five of whom were treated with CaEP. This is the first known application of CaEP to gynaecological cancers. Results: The median follow-up time was 14 months (range 2–18 months). Within the cohort of patients, CaEP was applied a total of 10 times, achieving a complete response five times and partial response four times. Symptoms improved within six weeks for eight episodes following CaEP application. Beyond six weeks, symptoms eventually recurred in all patients and four patients required more than one CaEP procedure. CaEP was useful for palliation of distressing symptoms in one case of metastatic ovarian cancer. No intra-operative or post-operative complications have been reported to date. Conclusion: CaEP may be a promising short-term treatment in selected patients with recurrent VIN and vulval cancer, where other treatments had failed. If validated, it could provide an acceptable alternative where surgery is unacceptable. Long term follow-up is required to evaluate effects on recurrence.

Calcium; Electroporation; Ovarian cancer; Vulval cancer; VIN

[1] Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiologica Scandinavica. 2003; 177: 437–447.

[2] Matthiessen LW, Chalmers RL, Sainsbury G, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncologica. 2011; 50: 621–629.

[3] Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek JJ, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I–II trial. Cancers. 1993; 72: 3694–3700.

[4] Perrone AM, Galuppi A, Pirovano C, Borghese G, Covarelli P, De Terlizzi F, et al. Palliative Electrochemotherapy in Vulvar Carcinoma: Preliminary Results of the ELECHTRA (Electrochemotherapy Vulvar Cancer) Multicenter Study. Cancers. 2019; 11: 657.

[5] Corrado G, Cutillo G, Fragomeni SM, Bruno V, Tagliaferri L, Mancini E, et al. Palliative electrochemotherapy in primary or recurrent vulvar cancer. International Journal of Gynecologic Cancer. 2020; 30: 927–931.

[6] De Giorgi V, Scarfì F, Saqer E, Gori A, Tomassini GM, Covarelli P. The use of cisplatin electrochemotherapy in nonmelanoma skin cancers: a single-center study. Dermatologic Therapy. 2020; 33: e13547.

[7] Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated super-ficial metastases from malignant melanoma. British Journal of Surgery. 2012; 99: 821–830.

[8] Curatolo P, Quaglino P, Marenco F, Mancini M, Nardo T, Mortera C, et al. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Annals of Surgical Oncology. 2012; 19: 192–198.

[9] Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technology in Cancer Research Treatment. 2011; 10: 475–485.

[10] Miklavcic D, Sersa G, Brecelj E, Gehl J, Soden D, Bianchi G, et al. Electrochemotherapy: technological advancements for efficient electroporation-based treatment of internal tumors. Medical Biological Engineering Computing. 2012; 50: 1213–1225.

[11] Landstrom F, Ivarsson M, Von Sydow AK, Magnuson A, Von Beckerath M, Moller C. Electrochemotherapy-Evidence for Cell-type Selectivity in Vitro. Anticancer Research. 2015; 35: 5813–5820.

[12] Levine ZA, Vernier PT. Calcium and phosphatidylserine inhibit lipid electropore formation and reduce pore lifetime. Journal of Membrane Biology. 2012; 245: 599–610.

[13] Frandsen SK, Gissel H, Hojman P, Tramm T, Eriksen J, Gehl J. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Research. 2012; 72: 1336–1341.

[14] Plaschke CC, Gehl J, Johannesen HH, Fischer BM, Kjaer A, Lomholt AF, et al. Calcium electroporation for recurrent head and neck cancer: a clinical phase I study. Laryngoscope Investigative Otolaryngology. 2019; 4: 49–56.

[15] Szewczyk A, Gehl J, Daczewska M, Saczko J, Frandsen K, Kulbacka J. Calcium electroporation for treatment of sarcoma in preclinical studies. Oncotarget. 2018; 9: 11604–11618.

[16] ClinicalTrials.gov. Calcium Electroporation for the Treatment of Colorectal Cancer NCT03542214. Bethesda(MD) National Library of Medicine (US). 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03542214?term=N CT03542214&draw=2&rank=1 (Accessed: 9 December 2020).

[17] ClinicalTrials.gov. Calcium Electroporation for Early Colorectal Cancer NCT03694080. Bethesda(MD) National Library of Medicine (US). 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03694080?term=NCT03694080&draw=2&rank=1 (Accessed: 9 December 2020).

[18] Ragupathy K, Grandidge L, Strelley K, Wang H, Tidy J, Ragupathy K, et al. Early and late vulval cancer recurrences: are they different?Journal of Obstetrics and Gynaecology. 2016; 36: 518–521.

[19] Wallbillich J, Rhodes H, Milbourne AM, Munsell MF, Frumovitz M, Brown J, et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecologic Oncology. 2012; 127: 312–315.

[20] Yap JKW, O’Neill D, Nagenthiran S, Dawson CW, Luesley DM. Current insights into the aetiology, pathobiology, and management of local disease recurrence in squamous cell carcinoma of the vulva. Journal of Obstetrics and Gynaecology. 2017; 124: 946–954.

[21] Falk H, Matthiessen LW, Wooler G, Gehl J. Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. Acta Oncologica. 2018; 57: 311–319.

[22] Frandsen SK, Gehl J. A Review on Differences in Effects on Normal and Malignant Cells and Tissues to Electroporation-Based Therapies: a Focus on Calcium Electroporation. Technology in Cancer Research Treatment. 2018; 17: 1–6.

[23] Frandsen SK, Kruger MB, Mangalanathan UM, Tramm T, Mahmood F, Novak I, et al. Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation. American Association for Cancer Research. 2017; 77: 4389–4401.

[24] Hoejholt KL, Mužić T, Jensen SD, Dalgaard LT, Bilgin M, Nylandsted J, et al. Calcium electroporation and electrochemotherapy for cancer treatment: Importance of cell membrane composition investigated by lipidomics, calorimetry and in vitro efficacy. Scientific Reports. 2019; 9: 1–12.